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Abstract
Idiopathic pulmonary fibrosis is a devastating disease with poor prognosis. The pathogenic role of the lysophospholipid mediator
sphingosine-1-phosphate and its receptor S1PR2 in lung fibrosis is unknown. We show here that genetic deletion of S1pr2 strikingly
attenuated lung fibrosis induced by repeated injections of bleomycin in mice. We observed by using S1pr2  mice that S1PR2
was expressed in alveolar macrophages, vascular endothelial cells and alveolar epithelial cells in the lung and that S1PR2-
expressing cells accumulated in the fibrotic legions. Bone marrow chimera experiments suggested that S1PR2 in bone marrow–
derived cells contributes to the development of lung fibrosis. Depletion of macrophages greatly attenuated lung fibrosis. Bleomycin
administration stimulated the mRNA expression of the profibrotic cytokines IL-13 and IL-4 and the M2 markers including arginase 1,
Fizz1/Retnla, Ccl17 and Ccl24 in cells collected from broncho-alveolar lavage fluids (BALF), and S1pr2 deletion markedly
diminished the stimulated expression of these genes. BALF cells from bleomycin–administered wild-type mice showed a marked
increase in phosphorylation of STAT6, a transcription factor which is activated downstream of IL-13, compared with saline–
administered wild-type mice. Interestingly, in bleomycin–administered S1pr2  mice, STAT6 phosphorylation in BALF cells was
substantially diminished compared with wild-type mice. Finally, pharmacological S1PR2 blockade in S1pr2  mice alleviated
bleomycin–induced lung fibrosis. Thus, S1PR2 facilitates lung fibrosis through the mechanisms involving augmentation of IL-13
expression and its signaling in BALF cells, and represents a novel target for treating lung fibrosis.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease with a poor median survival of 2–3 years after
diagnosis [1–3]. IPF is characterized by deposition of extracellular matrix proteins including collagens and fibronectin and fibroblast
proliferation, which result in chronic pathological remodeling of lung and eventually respiratory failure. IPF is likely elicited by
persistent injury of alveolar epithelial and vascular endothelial cells, which is accompanied by the infiltration of leukocytes into
injured sites. These damaged cells and infiltrating leukocytes release inflammatory cytokines and profibrogenic factors such as
interleukin (IL)-33, IL-4, IL-13 and transforming growth factor-β (TGFβ), which may act in linear or parallel pathways. The cytokines
and profibrogenic factors activate resident fibroblasts to induce differentiation into myofibroblasts, which robustly produce
extracellular matrix proteins to form fibrotic lesions [4]. Particularly, the importance of IL-4 and IL-13, which are T helper type 2
cytokines and act mainly through phosphorylating STAT6, are increasingly recognized as the critical profibrogenic mediators in lung
fibrosis [1–4]. In addition, bone marrow (BM)–derived circulating fibrocytes, and pericytes–and epithelial cells–derived fibroblasts
may also contribute to myofibroblasts in fibrotic lesions. Although the pathogenesis of IPF has been extensively studied, the precise
molecular and cellular pathogenesis for IPF is not fully understood and effective therapeutic strategies are still lacking.
Sphingosine-1-phosphate (S1P) is a pleiotropic lysophospholipid mediator and regulates various biological processes such as
embryonic development, vascular formation, vascular barrier integrity and lymphocyte trafficking via five members of S1P–specific
G protein–coupled receptors (S1PR1–S1PR5) [5]. Several lines of evidence suggested the possible involvement of S1P signaling in
lung fibrosis [6, 7]. S1P increased the expression of the myofibroblast marker α-smooth muscle actin and collagen synthesis in
cultured fibroblasts [8, 9]. Knockdown of either S1PR2, S1PR3 or the S1P–synthesizing enzyme sphingosine kinase-1 (SphK1)
inhibited TGFβ–induced myofibroblast differentiation in vitro, suggesting the participation of S1P signaling in the profibrotic actions
of TGFβ [10]. In mouse models of lung fibrosis, S1PR1 was shown to inhibit lung fibrosis [11] whereas S1PR3 mediated the
development of lung fibrosis [12]. In patients with IPF, S1P concentrations in serum and bronchoalveolar lavage fluid (BALF) were
elevated with the increased expression of SphK1 in the lung tissues [13].
Among S1PRs, S1PR2 exerts a unique inhibitory effect on migration of monocytes/macrophages [14] and mast cells [15], a
facilitating effect of myofibroblast differentiation [8, 9, 16], and a protective effect on vascular barrier integrity [17]. Hence, we
focused on S1PR2 in this study that aimed at revealing a role of S1P signaling in lung fibrosis. We found that genetic deletion of
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S1pr2 dramatically inhibited bleomycin–induced lung fibrosis through the mechanisms involving the potentiation of the responses to
the profibrotic cytokine IL-13. These findings suggest that targeting S1PR2 may offer a novel therapeutic strategy for lung fibrosis.
Materials and methods
Reagents
Rabbit monoclonal anti–Tyr –phosphorylated STAT6 (p-STAT6) antibody (ab54461) and rabbit monoclonal anti–STAT6 antibody
(ab32520) were bought from Abcam (Cambridge, MA). Rabbit monoclonal anti–Tyr –phosphorylated STAT1 (p-STAT1) antibody
(#9167) and rabbit polyclonal anti–STAT1 antibody (#9172) were bought from Cell Signaling Technology (Beverly, MA). Goat
polyclonal anti–platelet–derived growth factor (PDGF) receptor α antibody (AF1062) was bought from Roche (Nutley, NJ). Rat
monoclonal anti-Mac3 antibody (550292) was bought from BD Pharmingen (San Diego, CA). Bleomycin was bought from Nippon
Kayaku (Tokyo, Japan). 4-[2((1R,2R)-2-Hydroxycyclohexylamino)-benzothiazol-6-yloxyl]-pyridine- 2-carboxylic acid methylamide
(BLZ945) was purchased from Chemshuttle (Jiangsu, China). Rat monoclonal IgG  anti-mouse IL-13 antibody (38213) and control
rat monoclonal IgG  (54447) were bought from R&D systems (Minneapolis, MN). 4’6-diamidino-2-phenylindole (DAPI) (D1306)
was purchased from Molecular Probes (Eugene, OR). FastStart Universal SYBR Green Master was bought from Roche (Nutley,
NJ). All other reagents were bought from Wako (Osaka, Japan) unless otherwise specified. An S1PR2–specific antagonist (S1PR2i)
[18] was provided by Ono Pharmaceutical Co.
Mice
S1pr2–null mice with targeted disruption of the S1pr2 gene (S1pr2 ) (129Ola;C57BL/6J mixed background) that had been
backcrossed to C57BL/6J mice (Charles River) once were previously described [19]. S1pr2  and control wild-type littermate mice
were obtained using a heterozygous breeding strategy, and the latter mice were employed as appropriate controls. S1pr2
mice in which LacZ is knocked in at the S1pr2 locus (129Ola;C57BL/6J mixed background) were more than 10 times backcrossed
to C57BL/6J mice [19]. Col1α2–EGFP transgenic mice [20] were mated to S1pr2  mice to generate S1pr2 ; Col1α2–EGFP mice.
Mice were housed in a temperature-controlled conventional facility (24°C) under a 12:12 h light–dark cycle with free access to
regular chow and water. Mice were sacrificed at each observational time point using intraperitoneal pentobarbital (Kyoritsu, Tokyo,
Japan) overdose according to the acceptable euthanasia guidelines. Mice were genotyped by PCR analysis of genomic DNA
prepared from tail biopsies. All animal experiments were conducted according to the Fundamental Guidelines for Proper Conduct of
Animal Experiment and Related Activities in Academic Research Institutions under the jurisdiction of the Ministry of Education,
Culture, Sports, Science and Technology of Japan, and were approved by the Committee on Animal in Kanazawa University. We
did not perform a priori power analyses, and the sample sizes were chosen in this study so that the sample sizes became similar to
those generally employed in the field. In addition, all efforts were made to minimize animal suffering and to reduce the number of
animals required.
Bleomycin-induced lung fibrosis model
To induce lung fibrosis, mice (8–10 week-old, 20–25 g body weight) were challenged with i.p. injections of bleomycin at 0.035 U/g
twice weekly for 4 weeks [21, 22]. Control animals received intraperitoneal 150 μl sterile 0.9% saline. Mice were euthanized for
analysis 1 week after the final injection. During the period of bleomycin administration S1pr2  and wild-type mice showed 15% and
23% reductions in the average values of body weight, respectively. In contrast, the saline groups of S1pr2  and wild-type mice
showed 5% and 9% increases in body weight. For administration of BLZ945, BLZ945 was dissolved in 20% Captisol at a
concentration of 12.5 mg/ml and given to mice at the dose of 200 mg per kg body weight by oral gavage once daily [23]. In parallel,
control mice received 20% Captisol or none. For neutralization of IL-13, mice received 5 mg per kg body weight of monoclonal anti-
IL-13 antibody or control IgG in Dulbecco’s phosphate buffered saline (PBS) by i.p. injection every 11 days, beginning 1 day before
starting bleomycin injection. For administration of S1PR2i to mice, S1PR2i was powdered and mixed into the powder diet at 0.06%
(wt/wt) [18]. Mice were fed the powder diet with or without S1PR2i ad libitum, beginning 3 days before starting bleomycin
administration. The amounts of S1PR2i administered into mice were calculated from weights of ingested powder diet.
Determination of fibrotic regions
Mice were euthanized by pentobarbital overdose and the lungs were quickly inflated by injecting 0.5% low-melting point agarose
(Agarose XP) (Wako) and 4% paraformaldehyde (PFA) in PBS into the trachea via a blunted 18-gauge needle. Isolated lungs were
embedded in paraffin. Sections were cut 5-μm thick, followed by staining with Sirius Red to assess extents of fibrotic deposition, as
described [24]. To quantitate Sirius Red staining–positive pixels, images of three sagittal sections through hilar levels, central levels
and peripheral levels per each left whole lung were acquired at 4x objective magnification using BZ-II Analyzer software (Keyence,
Osaka, Japan) on a BIOREVO BZ-9000 microscope (Keyence, Osaka, Japan). Images were then converted into 8-bit grey-scale
TIFF files using the ImageJ software (NIH ImageJ; http://rsbweb.nih.gov/ij/). Areas of parenchyma were manually outlined to
exclude airways and large vessels and then thresholded with visual comparison being made to the images to ensure that the tool
effectively resolved Sirius Red–stained fibrotic lesions. Data were expressed as fibrotic region versus total lung area without
airways and large vessels. Fibrotic regions were determined in all of the three sagittal sections per each left lung, and finally the
mean value of the determinations of the three sections was calculated and taken as the fibrotic score of each mouse. To avoid bias,
evaluations were made in a blinded fashion.
Immunohistochemistry and 5-bromo-4-chloro-3-indolyi-β-D-galactopyranoside (X-gal) staining
The deparaffinized lung sections were incubated in Target Retrieval Solution (DAKO, Carpinteria, CA) at boiling temperature for 30
min to retrieve antigen before quenching endogenous peroxidase activity with 3% H O  in PBS for 15 min at room temperature.
The sections were blocked in Protein block Serum Free (DAKO) for 1 hour, and then incubated overnight at 4°C in goat polyclonal
anti–PDGFRα antibody (1:200). Sections were then incubated in biotinylated anti-goat IgG (1:200) and in ABC reagents (Vectastain
ABC kit) (Vector Laboratories, Burlingame, CA) for 1 hour at room temperature. Signals were visualized with DAB solution (0.05%
DAB and 0.03% H O  in PBS). Parallel sections processed identically but without the incubation in the primary antibody served as
negative controls. Finally, sections were washed, counterstained with hematoxylin. Image acquisition was carried out with a DP20
camera attached to a standard bright-field microscope (BX 41 (Olympus, Tokyo, Japan)). X-gal staining was prepared as previously
described [19].













Mice were anesthetized by i.p. injections of sodium pentobarbital (70 mg/kg), their tracheas were cannulated, and BALF was
collected by instilling 1 ml of sterile PBS into the trachea twice via a blunted 18-gauge needle. Recovery of the fluid was
consistently 70–80% of the total. For determination of total number of cells in BALF, the BALF was then centrifuged at 1,000 rpm for
10 min at 4°C, and the cell-free supernatant was collected and stored at -80°C until analysis. The cell pellets were resuspended in
1 ml PBS and counted with an automated cell counter (TC50 Automated Cell Counter) (Bio-Rad, Hercules, CA). The remaining
cells were centrifuged and resuspended in a small amount of a buffer at ~10  cells/μL. Five μL of the cell suspension was spotted
on slide glasses, and extended with a cover glass to make a thin film of the cell suspension. Slide glasses were air-dried and
stained with Diff-Quick stain (Sysmex, Kobe, Japan). The percentages of macrophages, lymphocytes and neutrophils were
determined by counting a minimum of 200 cells per slide under a BX 41 bright-field microscope. Soluble collagen content in BALF
was determined using the Sircol Soluble Collagen Assay kit (Biocolor, Northern Ireland, UK) according to the manufacturer’s
instructions. Total protein concentrations in BALF were determined by Lowry’s method as described previously [25].
RNA isolation and quantitative polymerase chain reaction (qPCR)
RNA isolation from BALF cells and qPCR were performed as previously described [26]. The housekeeping gene β-actin was used
as an internal control. Primers are listed in S1 Table. An average threshold cycle (Ct) value was calculated from duplicate results for
each RNA sample and was normalized to that of β-actin to obtain the ΔCt value.
Bone marrow transplantation
BM chimeras were prepared as previously described with minor modifications [27]. Briefly, recipient WT and S1pr2  mice aged 8–
10 weeks were irradiated 1 day before BMT by a sublethal dosage of 4.8 Gy twice at 3-hour intervals. Bone marrow cells were
collected by flushing the marrow cavity of femurs and tibias of donor WT and S1pr2  mice. Unfractionated bone marrow cells (1 x
10  cells per recipient) were injected into recipient mice via a tail vein. Analysis with a fluorescence activated cell sorter showed that
peripheral blood cells of the recipients were almost completely (~90%) reconstituted with donor BM-derived cells after one month.
All mice were injected with bleomycin 6 weeks after transplantation.
Microarray
Two independent RNA samples of each genotype were used to verify reproducibility of the microarray analyses. RNA sample
quality was assessed using the Tapestaion 2200 (Agilent Technologies, Santa Clara, CA). One-color microarray analysis was
performed according to the Agilent 60-mer Oligo Microarray Processing Protocol (Agilent Technologies). Total RNA samples (200
ng) were used to prepare Cy3-labeled cRNA using the Low Input Quick Amp Labeling Kit (Agilent Technologies). Hybridization
solutions containing fragmented cRNAs (1650 ng) were then applied to the Agilent 026655 whole mouse genome Microarray 4x44k
v2 that contains 44,000 probes for mouse genes (Agilent Technologies). The hybridized and washed arrays were scanned in the
Cy3 channel using an Agilent microarray scanner (G2565BA; Agilent Technologies). The images were analyzed using Feature
Extraction Software (Ver. 10.7.3.1; Agilent Technologies). These data were analyzed further with GeneSpring GX12.5 software
(Agilent Technologies). Normalization was performed as follows: 1, intensity-dependent Lowess normalization; 2, data
transformation, with measurements less than 0.01 set to 0.01; 3, per-chip normalization, in which the 75th percentile method was
used to normalize each array; 4, per-gene normalization, in which the data were normalized to control (wild-type) samples. After
normalization, statistically significant gene sets were defined as those exhibiting P values below the cut-off of 0.05. Genes with a
>1.5-fold change (FC) in expression ratio (S1pr2  vs wild-type) were identified. Thus, a combination of statistical analyses and FC
methods was used. The microarray data from this publication were deposited in GEO (accession number: GSE85411).
Western blot analysis
BALF cells were treated as indicated and lysed in the radioimmunoprecipitation assay (RIPA) buffer containing 50 mM Tris-HCl (pH
7.4), 150 mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1% NP-40 and cOmplete Mini (Roche, Nutley, NJ). The cell lysates were
centrifuged at 15,000 rpm for 15min at 4°C and the resultant supernatants were separated on SDS-8% polyacrylamide gels,
followed by electrotransfer onto Immobilon-P membrane (Millipore, Bedford, MA). The membranes were blocked with Tris-buffered
saline (pH 7.4) containing 0.1% Tween-80 and 5% non-fat dry milk for 1 hour at room temperature and probed with anti–p-STAT6
antibody (1:500 dilution), anti–p-STAT1 antibody (1:500), anti–STAT6 antibody (1:500), or anti–STAT1 antibody (1:500). The bound
antibodies were visualized using anti–rabbit IgG alkaline phosphatase–conjugated secondary antibody (1:1000) and 5-bromo-4-
chloro-3-indolyl phosphate and nitro blue tetrazolium. Relative quantification of proteins was determined by scanning and band
densitometry using Image Gauge software (Fuji Photo Film, Tokyo, Japan).
Determinations of cytokine concentrations
To prepare lung tissue homogenates for ELISA analysis, frozen lung tissues were homogenized at 50 mg wet tissues/ml in Hank’s
balanced salt solution. After being centrifuged at 800 g for 10 min, the supernatant from the lung homogenate was collected for
ELISA analysis [28]. The levels of IL-13 in BALF samples were determined with mouse IL-13 Mini ELISA Development Kit
(Peprotech), according to the manufacturer’s protocols.
Statistical analysis
All experiments were repeated at least three times. All data are presented as means ± SEM. Numbers of mice and samples
analyzed were indicated in the Figures. Statistical analyses were performed with Prism 6 software (GraphPad Software, La Jolla,
CA) using two-way ANOVA (multiple factor analysis) or one-way ANOVA, which was followed by the Bonferroni post-test, or two-
tailed Student’s t-test when comparing two groups. P < 0.05 was considered to indicate statistical significance.
Results
Genetic deletion of S1pr2 prevents bleomycin-induced pulmonary fibrosis
S1pr2  and S1pr2  littermates were subjected to repeated i.p. injections of bleomycin, which mimics chemotherapeutic regimen
in human patients and induces sustained lung fibrosis [21, 22]. Bleomycin–administered S1pr2  mice displayed attenuation of lung
fibrosis compared with wild-type mice, as evaluated with collagen staining (Fig 1A and 1B). In S1pr2  mice given bleomycin,
platelet-derived growth factor receptor α (PDGFRα)–positive fibroblasts of the lung were dramatically decreased compared with
wild-type mice (Fig 1C). In Col1α2–EGFP transgenic mice in which enhanced green fluorescent protein (EGFP) gene expression is
driven by the Col1α2 enhancer/promoter [20], bleomycin administration increased EGFP–positive cells in the lung sections (Fig











compared with Col1α2–EGFP mice (S1pr2 ), further supporting that S1pr2 deletion reduced fibroblast accumulation in the lung.
In addition, bleomycin–induced increases in fibronectin and collagen1α1 mRNAs in the lung were attenuated in S1pr2  mice
compared with wild-type mice (Fig 1E). Bleomycin induces inflammation in lung [29]. Bleomycin administration increased protein
concentrations and inflammatory cells in BALF of wild-type mice (Fig 1F and 1G). Approximately 70–80% of the cells in BALF of
bleomycin–administered mice were macrophages. Bleomycin administration increased macrophages in BALF of wild-type mice. In
S1pr2  mice given bleomycin, total cells and macrophages were reduced compared with wild-type mice (Fig 1F–1H). Bleomycin–
induced increase in the soluble collagen concentration of BALF was also attenuated in S1pr2  mice compared with wild-type mice
(Fig 1I). Thus, the loss of S1pr2 substantially suppressed pulmonary inflammation and fibrogenesis elicited by repeated
administration of bleomycin.
Fig 1. Genetic deletion of S1pr2 prevents bleomycin–induced lung fibrosis.
The lungs (A-E) and BALF (F-I) were collected from mice on day 33 after starting saline or bleomycin administration and
analyzed. (A) Representative images at low magnification (x40) of Sirius Red–stained whole lung sections from saline–or
bleomycin (Bleo)–administered wild-type (WT) and S1pr2  mice. Scale bar: 600 μm. (B) Quantification of fibrotic areas in
whole lung sections from WT and S1pr2  mice. (C) Representative images at high magnification (x400) of immunostaining
using anti-PDGFRα antibody and Sirius Red–stained lung sections from WT and S1pr2  mice. Scale bar:100 μm. (D)
Representative fluorescent images of EGFP fluorescence (green) and nuclear staining (DAPI, blue) in the lung from
Col1α2−EGFP and Col1α2−EGFP:S1pr2  mice. Magnification: x400. Scale bar: 50 μm. (E) mRNA expression levels of
Fibronectin and Collagen1a1 in the lung from WT and S1pr2  mice. (F-I) Total protein concentrations (F), total cell numbers
(G), Macrophage numbers (H) and soluble collagen levels (I) in BALF from WT and S1pr2  mice. The individual values and
the mean ± SEM are shown. N = 5−16 from three to seven independent experiments. *P <0.05, **P <0.01, ***P<0.001,
****P<0.0001 and n.s. no significance (two-way ANOVA followed by the Bonferroni post-test).
https://doi.org/10.1371/journal.pone.0197604.g001
Expression of S1PR2 in the lung of S1pr2  mice
In S1pr2  mice in which LacZ (Escherichia coli β-galactosidase) gene expression is driven by the endogenous S1pr2 promoter
[19], the lung among various organs examined was most intensely stained with X-gal chemical staining (Fig 2A), indicating that the
lung abundantly expresses S1PR2. In the alveolar area of saline–administered S1pr2  mice, it appears that the alveolar cells
and the interstitial cells were X-gal–positive (Fig 2B). In bleomycin–administered mice, X-gal–positive cells were abundant in the
fibrotic lesions of lung. The double staining of anti-Mac3 immunohistochemistry and X-gal chemical staining indicated that alveolar














Fig 2. Expression of S1PR2 in the lung of S1pr2  mice.
(A) X-gal stained brain, heart, lung, liver, spleen and kidney from 8-week old WT and S1pr2  mice. (B) X-gal stained lung
sections of S1pr2  mice on day 33 after starting administration of saline or bleomycin (Bleo). Magnification: x400. Scale
bar: 100 μm. (C) X-gal stained and anti–Mac3 immunostained lung sections of S1pr2  mice on day 33. Magnification:
x1000. Scale bar: 100 μm. (D) X-gal stained alveolar macrophages in the BALF smear from bleomycin–administered
S1pr2  mice. Magnification, x1000. Scale bar, 100 μm. In (B) and (D), the tissue sections were counterstained by nuclear
fast red. In (C) and (D), the arrowheads denote X-gal-stained macrophages. The presented data represent three independent
experiments.
https://doi.org/10.1371/journal.pone.0197604.g002
S1pr2 deletion in bone marrow–derived cells suppresses bleomycin–induced fibrosis
We studied the involvement of S1PR2 in bone marrow–derived cells in bleomycin–induced fibrosis using BM chimera mice (Fig 3).
Bleomycin–administered wild-type mice that received BM from S1pr2  donor mice exhibited a reduction in the lung fibrotic area
compared with wild-type mice receiving wild-type BM, while S1pr2  mice that received BM from wild-type mice showed
exaggeration of fibrosis compared with S1pr2  mice receiving BM from S1pr2  mice (Fig 3A and 3B). Wild-type and S1pr2  mice
that were both given wild-type BM tended to have higher soluble collagen concentrations in BALF compared with the respective
counterparts receiving S1pr2  BM, although not statistically significant (Fig 3C). Moreover, macrophages and total cells in BALF
were reduced in wild-type mice receiving S1pr2  BM compared with wild-type mice receiving wild-type BM while these parameters
were elevated in S1pr2  mice receiving wild-type BM compared with S1pr2  mice receiving S1pr2  BM (Fig 3D and 3E). These
data are compatible with the notion that S1PR2 in BM–derived cells are involved in bleomycin–induced fibrosis.
Fig 3. S1pr2 deletion in bone marrow–derived cells suppresses bleomycin–induced lung fibrosis in mice.
Wild-type (WT) and S1pr2  mice had been transplanted with BM from either WT or S1pr2  mouse donors. The lungs (A, B)
and BALF (C-E) were collected from BM–chimeric wild-type or S1pr2  mice. on day 33 after starting administration of saline
or bleomycin (Bleo) and analyzed. (A) Representative images of Sirius Red–stained whole lung sections Magnification: x40.
Scale bar: 600 μm. (B) Quantification of lung fibrotic lesions using image analysis of Sirius Red–stained lung sections. (C-E)
Soluble collagen levels (C), total cell numbers (D), and macrophage numbers (E) in BALF. The details of BM transplantation
are indicated on each image in (A) and at the bottoms of (B) to (E). The individual values and the mean ± SEM are shown. N
= 5−13 from five independent experiments. *P <0.05, **P <0.01, ***P<0.001 and n.s. no significance (two-way ANOVA















Although previous studies [30] showed that macrophage depletion resulted in inhibition of lung fibrosis in intratracheal single
bleomycin administration models, an involvement of macrophages in a repeated bleomycin injection model, which generates
persistent and more diffuse fibrotic lesions differently from intratracheal single bleomycin administration models [29], is unknown.
We tested the effects of the specific inhibitor (BLZ945) of the receptor for colony–stimulating factor-1 (CSF-1), which is a growth
factor necessary for differentiation, proliferation and survival of macrophages [23]. BLZ945 inhibited lung fibrosis with depletion of
alveolar macrophages in BALF whereas the vehicle did not affect fibrosis (Fig 4A and 4B). BLZ945 also reduced the levels in BALF
of soluble collagen, total proteins and total cells (Fig 4C–4E). Thus, depletion of macrophages suppressed bleomycin–induced lung
fibrosis. These results, together with the data in BM chimera experiments, suggest that S1PR2 in macrophages may be involved in
bleomycin–induced lung fibrosis.
Fig 4. A CSF-1 receptor inhibitor inhibits bleomycin–induced lung fibrosis in mice.
The CSF-1 receptor inhibitor BLZ945 (200 mg/kg, open circles), vehicle (20% Captisol) (closed circles) or saline (None group,
closed triangles) were administered into wild-type mice given bleomycin once daily by oral gavage. Control wild-type mice
(closed square) received i.p. injection of saline. The lungs (A) and BALF (B-E) were collected on day 25 after starting
bleomycin administration and analyzed. (A) Representative tissue images of Sirius Red–stained lung sections (Left).
Magnification, x400. Scale bar, 100 μm. Quantification of fibrotic areas in Sirius Red–stained lung sections (Right). N, none; V,
vehicle; B, BLZ945. (B-E) Macrophage numbers (B), soluble collagen levels (C), total protein concentrations (D), and total cell
numbers (E) in BALF. The individual values and the mean ± SEM are shown. N = 4−7 from the single experiments, except the
saline-administered wild-type control mice in which N was 20 from multiple experiments in (A) and 2 in (B-E). *P <0.05 (one-
way ANOVA followed by the Bonferroni post-test).
https://doi.org/10.1371/journal.pone.0197604.g004
S1pr2 deletion suppresses the expression of profibrotic genes in macrophages
We studied the effects of S1pr2 deletion on mRNA expression in BALF cells using DNA microarray analysis. In BALF cells from
bleomycin–administered S1pr2  mice, 398 genes showed downregulation by less than 0.5-fold compared with bleomycin–
administered wild-type BALF cells (GEO accession number: GSE85411). In contrast, 122 genes showed upregulation by more than
2.0-fold in S1pr2  BALF cells. The downregulated genes in S1pr2  mice included the genes of profibrotic cytokines, chemokines
and the markers characteristic of alternatively activated (M2) macrophages [31, 32] (Table 1). To confirm their differential
expression, we determined time–dependent changes in mRNA levels in BALF cells from bleomycin–or saline–administered wild-
type and S1pr2  mice, using qPCR. Bleomycin increased the expression of the profibrotic genes including Il4, Il13, Irf4 and Ctgf in
wild-type BALF cells on days 22 and 33 (Fig 5I, 5J, 5L and 5N). Bleomycin did not increase mRNA expression of the powerful
profibrotic factor TGFβ1 in either wild-type or S1pr2  cells (data not shown). Bleomycin also increased the expression of the “M2
marker” genes including Arg1, Fizz1/Resistin like alpha (Retnla)/Resistin–like molecule α (RELMa), Ccl17, Ccl24 and Alox15.
S1pr2 deletion markedly attenuated or abolished bleomycin–induced increases in the mRNA expression of the profibrotic genes as
well as M2 marker genes (Fig 5D–5H). Bleomycin also tended to increase the expression of some M1 marker genes including





Fig 5. S1pr2 deletion suppresses the expression of profibrotic genes in BALF cells.
The mRNA expression levels of M1 and M2 markers and related genes (A-N) in BALF cells from wild-type (WT) and S1pr2
mice on days 7, 22 and 33 after starting administration of bleomycin or saline were determined by qPCR. The open and solid
bars indicate the values of saline–and bleomycin (Bleo)–administered mice, respectively. The individual values and the mean
± SEM are shown. Each sample was prepared from the pooled cells obtained from 3–4 mice. N = 3−6 from three independent
experiments. *P <0.05, **P <0.01 and ***P<0.001 (two-way ANOVA followed by the Bonferroni post-test).
https://doi.org/10.1371/journal.pone.0197604.g005
Table 1. List of chemokines, cytokines, macrophage-related and extracellular matrix-related genes upregulated by more than 2.0-fold and
downregulated by less than 0.5-fold in S1pr2  BALF cells relative to wild-type BALF cells from bleomycin-treated mice by microarray analysis.
https://doi.org/10.1371/journal.pone.0197604.t001
Among the cytokines and chemokines that were upregulated by bleomycin administration and suppressed by S1pr2 deletion (Fig 5
and Table 1), IL-13 has recently emerged as a profibrotic mediator in lung fibrosis [33, 34]. Bleomycin administration increased IL-
13 concentrations in BALF in wild-type mice (Fig 6A). However, S1pr2 deletion did not affect IL-13 concentrations in BALF. We
tested a possible involvement of IL-13 in a repeated bleomycin injection model of lung fibrosis by studying the effect of anti-IL-13
antibody administration in mice. Administration of anti-IL-13 antibody into wild-type mice substantially inhibited bleomycin–induced
lung fibrosis compared with control IgG (Fig 6B and 6C). Consistent with this, administration of anti–IL-13 antibody reduced the
concentration of soluble collagen in BALF (Fig 6D) and tended to decrease total protein concentration, total cells and macrophages
(Fig 6E–6G). These results indicate that IL-13 plays a crucial role in bleomycin–induced lung fibrosis.
-/-
-/-
Fig 6. Administration of IL-13–neutralizing antibody ameliorates bleomycin–induced lung fibrosis.
(A) IL-13 protein levels in BALF. IL-13 levels in BALF from wild-type (WT) and S1pr2  mice on day 22 after starting saline or
bleomycin (Bleo) administration were measured by ELISA. The solid and open bars indicate the values of WT and S1pr2
mice, respectively. In (B)-(G), the mice received intraperitoneal injection of IL-13–neutralizing antibody (αIL-13) or control IgG
(IgG) (5 mg/kg, every 11 day), which was begun 1 day before starting bleomycin (Bleo) administration. The lungs and BALF
were collected from mice on day 33 and analyzed. (B) Representative images at low magnification (x40) of Sirius Red–
stained whole lung sections from wild-type mice given αIL-13 or IgG. Scale bar, 600 μm. (C) Left: Representative images at
high magnification (x400) of Sirius Red–stained lung sections. Scale bar, 100 μm. Right: Quantification of fibrotic areas in
whole lung sections. (D-G) Soluble collagen levels (D), total protein concentrations (E), total cell numbers (F), and
macrophage numbers (G) in BALF. The individual values and the mean ± SEM are shown. In (A), N = 6. In (C-G), N = 4−5
from the single experiment, except the saline-administered wild-type control mice in which N was 20 from multiple
experiments in (C) and 2 in (D-G). *P <0.05, **P <0.01, ****P<0.0001 (two-way ANOVA followed by the Bonferroni post-test in
(A) and two-tailed Student’s t-test in (C)-(G)).
https://doi.org/10.1371/journal.pone.0197604.g006
S1pr2 deletion dampens the response of macrophages to IL-13.
Macrophages are one of IL-13–target cells [35–37]. IL-13 and IL-4 signal through the receptor molecules IL-4Rα and IL-13Rα1 to
specifically phosphorylate and activate STAT6, leading to expression of IL-13/IL-4–regulated genes including Arg1 and Fizz1 [38].
We studied phosphorylation of STAT6 in freshly isolated BALF cells. The BALF cells from bleomycin–administered wild-type mice
showed an approximately 10-fold increase in the level of STAT6 phosphorylated at Tyr  (p-STAT6) compared with saline–
administered control mice (Fig 7A). The level of p-STAT6 was substantially reduced in BALF cells from bleomycin–administered
S1pr2  mice compared with wild-type counterpart. In contrast, bleomycin did not increase phosphorylation at Tyr  (p-STAT1) of
STAT1, which can be activated by interferon γ, in either wild-type or S1pr2  BALF cells. There was no difference in the mRNA
levels of Il4ra and Il13ra1 in BALF cells between wild-type and S1pr2  mice (Fig 7B and 7C), suggesting that the decrease of p-
STAT6 in S1pr2  BALF cells was not due to reduced receptor gene expression.
Fig 7. STAT6 activation is suppressed in S1pr2  macrophages.
(A) Tyrosine phosphorylation of STAT6 and STAT1 in alveolar macrophages freshly isolated from saline–or bleomycin (Bleo)–
administered wild-type (WT) and S1pr2  mice. Left: representative western blots. Right: quantified data. The open and solid
bars indicate the values of saline–and Bleo–administered mice, respectively. (B,C) mRNA expression levels of Il4ra (B) and
Il13ra1 (C) in BALF cells from WT and S1pr2  mice. The solid and open bars indicate the values of Bleo–and saline–
administered mice, respectively. Each sample was prepared from the pooled cells obtained from 8–13 mice. Lysates of IL-13-
stimulated BM–derived wild-type macrophages that had been induced to differentiate in the presence of CSF-1 were used as
a positive control. The means ± SEM are shown. N = 3−6 from three or four independent experiments. **P <0.01 and












Pharmacological blockade of S1PR2 attenuates lung fibrosis
We studied the effects of pharmacological blockade of S1PR2 on bleomycin–induced lung fibrosis. The S1PR2–specific antagonist,
S1PR2i, was orally administered into bleomycin–treated wild-type mice [18]. S1PR2i suppressed bleomycin–induced lung fibrosis
compared with vehicle–treatment (Fig 8A–8C). The level of soluble collagen in BALF from S1PR2i–treated mice was also
decreased compared with vehicle–treated wild-type mice (Fig 8D).
Fig 8. Pharmacological blockade of S1PR2 attenuates lung fibrosis.
The S1PR2 antagonist, S1PR2i, was orally administered into wild-type mice, which began 3 days before starting bleomycin
administration. The lungs and BALF were collected from mice on day 33 and analyzed. (A) Representative images at low
magnification (x40) of Sirius Red–stained whole lung sections from bleomycin–administered wild-type mice given S1PR2i or
vehicle. Scale bar: 600 μm. (B) Representative images at high magnification (x400) of Sirius Red–stained lung sections.
Scale bar: 100 μm. (C) Quantification of fibrotic areas in whole lung sections. (D) Soluble collagen levels in BALF. The
individual values and the mean ± SEM are shown. N = 8−12 from three independent experiments, except the saline-
administered wild-type control mice in which N was 20 from multiple experiments in (C) and 3 in (D). **P <0.01, ***P<0.001,
****P<0.0001 (one-way ANOVA followed by the Bonferroni post-test).
https://doi.org/10.1371/journal.pone.0197604.g008
Discussion
The present study first provides evidence for the involvement of S1PR2 in bleomycin–induced lung fibrosis. Second, among several
different lung cell types including macrophages, vascular endothelium and fibroblasts that express S1PR2, our studies suggest that
S1PR2 in BM–derived cells, most likely in macrophages, contributes to lung fibrosis. Third, mechanistically, S1PR2 is engaged in
the production of the profibrotic cytokine IL-13 and the STAT6 phosphorylation response in pulmonary macrophages upon
bleomycin administration. Fourth, pharmacological blockade of S1PR2 alleviated bleomycin–induced lung fibrosis, suggesting that
S1PR2 is a new promising target for treating lung fibrosis.
Macrophages are engaged in fibrogenesis by secreting profibrogenic factors that recruit and activate fibroblasts and differentiate
them into myofibroblasts [30, 32]. TGFβ is one of the best characterized profibrotic cytokines and considered a key player in the
pathogenesis of fibrosis. However, we did not find any differences in the protein levels of TGFβ1 in BALF and lung between wild-
type and S1pr2  mice. Besides secreting TGFβ, macrophages are an important source of yet other factors that regulate fibrosis,
which include PDGF, IGF-1, CTGF and osteopontin [37, 39, 40]. These factors act on fibroblasts to stimulate proliferation, survival
and migration, and to promote collagen synthesis. However, DNA microarray data showed no apparent differences in the mRNA
expression of these factors between wild-type and S1pr2  BALF cells, except CTGF, which was slightly diminished in S1pr2
BALF cells compared with wild-type BALF cells.
IL-13 and IL-4 have emerged as key mediators of inflammation–and infection–driven fibrosis. Previous studies [34, 41, 42] showed
that bleomycin–induced lung fibrosis was diminished in mice deficient in IL-13, IL-4 and their downstream transcription factor
STAT6 or treated with a neutralizing anti–IL-13 antibody. In these previous investigations, single bleomycin intratracheal
administration protocols were employed. In contrast, our study used repeated bleomycin i.p. administration protocol, which
generates substantial differences in progression, persistence and distribution of lung fibrotic lesions from single intratracheal
administration models [22, 29]. Our data indicate that IL-13 is a key driver for the repeated injection model of lung fibrosis (Fig 6).
IL-13 and IL-4 in part share the receptors and the downstream signaling pathway to drive the differentiation of macrophages toward
the phenotype known as alternative activation or M2 activation, which is characterized by upregulated expression of the genes
including FIZZ1 and arginase 1, [37, 43]. The increased expression of these genes is mediated largely through activation of STAT6.
Among these molecules, the secreted protein FIZZ1 was shown to act on fibroblasts and induce differentiation into myofibroblasts
and stimulation of collagen synthesis [44].
Bleomycin–induced stimulation of IL-13/IL-4 expression in BALF cells was markedly reduced in S1pr2  BALF cells. Although T
helper 2 (Th2) cells were initially implicated as the major source of IL-13 in the development of fibrosis [37], type II innate lymphoid
cells (ILC2s) of the innate immune cell members are more recently emerging as an important source of IL-13 [35]. In addition,
recent studies showed that IL-33, an IL-1 family member, activates macrophages to stimulate IL-13 expression [45, 46]. However,
in the present study, bleomycin induced the similar extents of increases in IL-13 protein level in BALF (Fig 6A) in wild-type and
S1pr2  mice in the face of the markedly reduced IL-13 mRNA level in S1pr2  BALF cells (Fig 5J). These data may suggest that
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Activation of STAT6, a downstream essential effector of IL-13/IL-4, in BALF cells was 70% reduced in bleomycin–administered
S1pr2  mice compared with bleomycin–administered wild-type mice (Fig 7A). Because IL-13 protein levels were similar in BALFs
of wild-type and S1pr2  mice, these observations suggest that S1PR2 may be involved in lung fibrosis mainly through potentiating
cellular responses to the key profibrotic mediator IL-13 rather than stimulating the production of IL-13 in lung. In cytokine signaling,
tyrosine phosphorylation of STAT is catalyzed by Janus kinases and also negatively regulated by tyrosine phosphatases and
suppressor of cytokine signaling (SOCS) proteins [47–49]. The regulation of STAT6–specific tyrosine phosphatases, which include
SHP-1 and PTP1B, is not well understood and the possibility of tyrosine phosphatase inhibition by S1PR2 remains to be clarified in
future studies. In the present study, we observed changes in the expression of some SOCS members in S1pr2  BALF cells (Table
1). In any event, these observations collectively suggest that S1pr2 deletion in BALF cells impedes STAT6 activation and thereby
inhibits the expression of STAT6–targeted profibrotic genes including Fizz1, leading to the attenuation of lung fibrosis.
S1PRs seem to exert receptor subtype–specific distinct effects on lung fibrosis. In contrast to S1PR2 blockade, the functional
antagonism of S1PR1 by continuous administration of an S1PR1 agonist, which brought about robust S1PR1 internalization and
consequent downregulation of cell surface S1PR1 in the vascular endothelium, led to aggravation of lung fibrosis due to impaired
vascular barrier integrity [5,11]. In this point, it is notable that the major site of S1PR2 action in lung fibrosis is likely BM–derived
cells. Also, the signaling property of S1PR2 is distinct from that of S1PR1: S1PR1 is exclusively coupled to G  signaling pathway
whereas S1PR2 is coupled to G  pathway [5]. More recently, S1pr3 deletion was reported to attenuate bleomycin–induced lung
fibrosis [12]. However, the S1PR3–expressing cell type that plays a crucial role in lung fibrosis, and the critical intracellular signaling
pathway downstream of S1PR3 are unknown.
In summary, our study demonstrates a novel role for S1PR2 in regulating cellular phenotypes of BM–derived cells, particularly
macrophage, and resultantly fibrogenesis during the development of bleomycin–induced pulmonary fibrosis. The profibrotic effects
of S1PR2 are suggested to be mediated largely through augmented responses of the cells including macrophages to IL-13. This
work also suggests that targeting S1PR2 offers a new therapeutic strategy for IPF.
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